CA2408913A1 - Melanin-concentrating hormone antagonist - Google Patents

Melanin-concentrating hormone antagonist Download PDF

Info

Publication number
CA2408913A1
CA2408913A1 CA002408913A CA2408913A CA2408913A1 CA 2408913 A1 CA2408913 A1 CA 2408913A1 CA 002408913 A CA002408913 A CA 002408913A CA 2408913 A CA2408913 A CA 2408913A CA 2408913 A1 CA2408913 A1 CA 2408913A1
Authority
CA
Canada
Prior art keywords
substituted
group
ring
compound
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002408913A
Other languages
English (en)
French (fr)
Inventor
Yuji Ishihara
Jun Terauchi
Nobuhiro Suzuki
Shiro Takekawa
Kazuyoshi Aso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2408913A1 publication Critical patent/CA2408913A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/341,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/361,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
CA002408913A 2000-05-16 2001-05-15 Melanin-concentrating hormone antagonist Abandoned CA2408913A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2000148647 2000-05-16
JP2000-148647 2000-05-16
JP2001116219 2001-04-13
JP2001-116219 2001-04-13
PCT/JP2001/004015 WO2001087834A1 (fr) 2000-05-16 2001-05-15 Antagoniste de l'hormone de concentration de la melanine

Publications (1)

Publication Number Publication Date
CA2408913A1 true CA2408913A1 (en) 2001-11-22

Family

ID=26592253

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002408913A Abandoned CA2408913A1 (en) 2000-05-16 2001-05-15 Melanin-concentrating hormone antagonist

Country Status (5)

Country Link
US (1) US7229986B2 (US07229986-20070612-C00097.png)
EP (1) EP1283199A4 (US07229986-20070612-C00097.png)
AU (1) AU2001256733A1 (US07229986-20070612-C00097.png)
CA (1) CA2408913A1 (US07229986-20070612-C00097.png)
WO (1) WO2001087834A1 (US07229986-20070612-C00097.png)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1310490A4 (en) * 2000-07-04 2004-03-17 Takeda Chemical Industries Ltd GPR14 ANTAGONIST
AU2001279294A1 (en) 2000-07-06 2002-01-21 Neurogen Corporation Melanin concentrating hormone receptor ligands
US6706751B2 (en) 2000-12-21 2004-03-16 Hoffman-La Roche Inc. Dihydroindole and tetrahydroquinoline derivatives
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
JP2004529161A (ja) 2001-05-04 2004-09-24 トゥラリック インコーポレイテッド 縮合複素環式化合物
EP1389189A2 (en) 2001-05-22 2004-02-18 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
CA2467857C (en) 2001-11-26 2010-08-24 Duane A. Burnett Piperidine-based mch antagonists for treatment of obesity and cns disorders
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
CA2472470A1 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
EP1465635A4 (en) 2002-01-10 2005-04-13 Neurogen Corp MELANIN-CONCENTRATING HORMONIC RECEPTOR LIGANDS: SUBSTITUTED 2- (4-BENZYL-PIPERAZIN-1-YLMETHYL) AND 2- (4-BENZYL-DIAZEPAN-1-YLMETHYL) -1H-BENZOIMIDAZOLE ANALOGUES
US7314937B2 (en) 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
DE10238865A1 (de) * 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
EA009421B1 (ru) 2002-11-06 2007-12-28 Эмджен Инк. Конденсированные гетероциклические соединения
WO2004041266A1 (ja) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited 受容体機能調節剤
NZ540148A (en) * 2002-12-20 2007-11-30 Glaxo Group Ltd Benzazepine derivatives for the treatment of neurological disorders
GB0229820D0 (en) * 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JPWO2004069798A1 (ja) * 2003-02-10 2006-05-25 萬有製薬株式会社 ピペリジン誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
WO2004080411A2 (en) 2003-03-07 2004-09-23 Neurocrine Biosciences, Inc. Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto
CA2551037A1 (en) 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. Novel piperidine derivative
JP2007508303A (ja) 2003-10-01 2007-04-05 ザ プロクター アンド ギャンブル カンパニー メラニン凝集ホルモン拮抗物質
WO2005040824A2 (en) * 2003-10-24 2005-05-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24)
BRPI0414979A (pt) 2003-10-31 2006-11-21 Takeda Pharmaceutical preparação sólida
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
WO2005085200A1 (ja) * 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. ピリドン誘導体
US7605176B2 (en) 2004-03-06 2009-10-20 Boehringer Ingelheim International Gmbh β-ketoamide compounds with MCH antagonistic activity
EP1731505B1 (en) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
JP2008502644A (ja) * 2004-06-18 2008-01-31 グラクソ グループ リミテッド ヒスタミンh3アンタゴニストとしての3−シクロアルキルベンズアゼピン
EP2127676A3 (en) * 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related disorders
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
MX2007007226A (es) * 2004-12-17 2007-08-21 Lilly Co Eli Antagonistas receptores novedosos de hormona concentradora de melanina (mch).
ES2333243T3 (es) * 2004-12-17 2010-02-18 Eli Lilly And Company Derivados de tiazolopiridinona como antagonistas del receptor de mch.
US20090286723A1 (en) 2005-02-11 2009-11-19 Amylin Pharmaceuticals, Inc. Hybrid Polypeptides with Selectable Properties
EP2332909B1 (en) 2005-04-13 2014-10-15 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of hsp90
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP1876179B1 (en) * 2005-04-28 2015-03-25 Takeda Pharmaceutical Company Limited Thienopyrimidone compounds
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
NZ562766A (en) 2005-05-30 2011-03-31 Banyu Pharma Co Ltd Piperidine derivatives as histamine-H3 receptor antagonists
PT1897558E (pt) 2005-06-09 2013-11-06 Norgine Bv Preparação sólida de 2-hexadeciloxi-6-metil-4h-3,1- benzoxazin-4-ona
US20100216758A1 (en) 2005-08-10 2010-08-26 Makoto Ando Pyridone Compounds
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
EP1921065B1 (en) 2005-08-24 2010-10-20 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP1939194A4 (en) 2005-09-07 2010-12-08 Banyu Pharma Co Ltd AROMATIC SUBSTITUTED BICYLIC PYRIDONE DERIVATIVE
WO2007041052A2 (en) 2005-09-29 2007-04-12 Merck & Co., Inc. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
KR20080059233A (ko) 2005-10-21 2008-06-26 노파르티스 아게 레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물
JPWO2007049798A1 (ja) 2005-10-27 2009-04-30 萬有製薬株式会社 新規ベンゾオキサチイン誘導体
KR101318127B1 (ko) 2005-11-10 2013-10-16 엠에스디 가부시키가이샤 아자 치환된 스피로 유도체
JP5094416B2 (ja) 2005-12-28 2012-12-12 武田薬品工業株式会社 糖尿病治療剤
US7754725B2 (en) * 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
EP2009011A1 (en) 2006-04-14 2008-12-31 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
FR2902790A1 (fr) * 2006-06-27 2007-12-28 Sanofi Aventis Sa Derives d'urees de piperidine ou pyrrolidine,leur preparation et leur application en therapeutique
WO2008001778A1 (fr) 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Animal génétiquement modifié et son utilisation
CN103070854A (zh) 2006-06-27 2013-05-01 武田药品工业株式会社 稠环化合物
PE20080212A1 (es) 2006-06-27 2008-04-25 Sanofi Aventis Derivados de ureas de piperidina o pirrolidina como moduladores de la 11b-hidroxiesteroide deshidrogenasa tipo 1 (11bhsd1)
PE20080344A1 (es) 2006-06-27 2008-06-09 Sanofi Aventis Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1
WO2008016131A1 (fr) 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Composé hétérocyclique à cycles fusionnés
CA2660704A1 (en) 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
EP2072519A4 (en) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd DIARYLKETIMINDERIVAT
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
EP2073804B1 (en) 2006-10-12 2017-09-13 Astex Therapeutics Limited Hydroxy-substituted benzoic acid amide compounds for use in the treatment of pain
US8883790B2 (en) * 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
WO2008044027A2 (en) * 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical compounds having hsp90 inhibitory or modulating activity
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
EP2073802A1 (en) * 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
WO2008047821A1 (fr) 2006-10-18 2008-04-24 Takeda Pharmaceutical Company Limited Composé hétérocyclique fusionné
MY158052A (en) 2006-10-19 2016-08-30 Takeda Pharmaceutical Indole compound
JP2010510962A (ja) 2006-11-24 2010-04-08 武田薬品工業株式会社 複素単環化合物およびその用途
JPWO2008090944A1 (ja) 2007-01-25 2010-05-20 武田薬品工業株式会社 スピロ環化合物
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
US20080186971A1 (en) * 2007-02-02 2008-08-07 Tarari, Inc. Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
JPWO2008102749A1 (ja) 2007-02-20 2010-05-27 武田薬品工業株式会社 複素環化合物
US8106086B2 (en) 2007-04-02 2012-01-31 Msd K.K. Indoledione derivative
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素5員複素環化合物
WO2008143262A1 (ja) 2007-05-21 2008-11-27 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
TW200914006A (en) 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
UA98799C2 (ru) * 2007-07-19 2012-06-25 Такеда Фармасьютикал Компани Лимитед Твердый препарат, включающий алоглиптин и гидрохлорид метформина
EP2202223B1 (en) 2007-10-18 2017-01-25 Takeda Pharmaceutical Company Limited Heterocyclic compound as blood rbp4 lowering agent
US8309580B2 (en) 2007-11-01 2012-11-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR20100098628A (ko) * 2007-11-14 2010-09-08 아밀린 파마슈티칼스, 인크. 비만 및 비만 관련 질환 및 장애의 치료 방법
MY157189A (en) 2008-01-10 2016-05-13 Takeda Pharmaceutical Capsule formulation
US8436043B2 (en) 2008-03-05 2013-05-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2009110510A1 (ja) 2008-03-06 2009-09-11 萬有製薬株式会社 アルキルアミノピリジン誘導体
WO2009119726A1 (ja) 2008-03-28 2009-10-01 萬有製薬株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
WO2009123194A1 (ja) 2008-04-01 2009-10-08 武田薬品工業株式会社 複素環化合物
WO2009123316A1 (ja) 2008-04-04 2009-10-08 武田薬品工業株式会社 複素環誘導体及びその用途
GB0806527D0 (en) * 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
US8349886B2 (en) 2008-04-16 2013-01-08 Takeda Pharmaceutical Company Limited Nitrogenated 5-membered heterocyclic compound
WO2009145286A1 (ja) 2008-05-30 2009-12-03 武田薬品工業株式会社 複素環化合物
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2009154132A1 (ja) 2008-06-19 2009-12-23 萬有製薬株式会社 スピロジアミン-ジアリールケトオキシム誘導体
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
JP2011528341A (ja) * 2008-07-18 2011-11-17 武田薬品工業株式会社 ベンズアゼピン誘導体及びそれらのヒスタミンh3拮抗薬としての使用
US20110124674A1 (en) 2008-07-30 2011-05-26 Hiroyuki Kishino 5/5-or 5/6-membered condensed ring cycloalkylamine derivative
WO2010016552A1 (ja) 2008-08-07 2010-02-11 武田薬品工業株式会社 過敏性腸症候群治療薬
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
EP2351743A4 (en) * 2008-10-27 2012-05-09 Takeda Pharmaceutical BICYCLIC CONNECTION
AU2009308980B2 (en) 2008-10-30 2013-02-28 Merck Sharp & Dohme Corp. Isonicotinamide orexin receptor antagonists
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
JPWO2010087454A1 (ja) 2009-01-30 2012-08-02 武田薬品工業株式会社 キノリン誘導体
ES2350077B1 (es) * 2009-06-04 2011-11-04 Laboratorios Salvat, S.A. Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1.
WO2011083316A1 (en) 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Benzazepine derivatives for the treatment of central nervous system disorders
WO2011083315A1 (en) 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Compounds and their use
AR079851A1 (es) 2010-01-08 2012-02-22 Takeda Pharmaceutical Derivados de benzazepina para tratamiento de desordenes en el sistema nervioso central
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
EP2563765B1 (en) 2010-04-27 2015-05-27 Takeda Pharmaceutical Company Limited Bicyclic compound derivatives and their use as acc inhibitors.
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
PE20140161A1 (es) 2010-11-30 2014-02-19 Takeda Pharmaceutical Compuesto biciclico
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
CN105001219A (zh) 2011-02-25 2015-10-28 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
TW201311679A (zh) 2011-08-04 2013-03-16 Takeda Pharmaceutical 含氮雜環化合物
UY34365A (es) 2011-10-07 2013-05-31 Takeda Pharmaceutical Compuestos heterociclicos
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
CA2853221A1 (en) 2011-10-24 2013-05-02 Tohru Yamashita Bicyclic compound
ES2640258T3 (es) 2012-02-24 2017-11-02 Takeda Pharmaceutical Company Limited Compuesto anular aromático como inhibidor de grelina o-aciltransferasa
CN104350040B (zh) 2012-03-29 2016-06-01 武田药品工业株式会社 芳环化合物
EP2871179A4 (en) 2012-07-03 2016-03-16 Ono Pharmaceutical Co CONNECTION WITH AGONISTIC EFFECT ON THE SOMATOSTATIN RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9296746B2 (en) 2012-10-16 2016-03-29 Takeda Pharmaceutical Company Limited Heterocyclic compound
UA115156C2 (uk) 2012-12-11 2017-09-25 Такеда Фармасьютікал Компані Лімітед Гетероциклічна сполука
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 抗糖尿病二環式化合物
EP2970331B1 (en) 2013-03-14 2017-05-17 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2982670B1 (en) 2013-04-04 2018-11-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2982666B1 (en) 2013-04-04 2019-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
KR102272746B1 (ko) 2013-06-05 2021-07-08 보슈 헬스 아일랜드 리미티드 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법
HUE043374T2 (hu) 2013-09-30 2019-08-28 Ono Pharmaceutical Co Vegyület, amelynek van szomatosztatin receptor agonista aktivitása és annak gyógyszerészeti felhasználása
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP6533799B2 (ja) 2014-06-09 2019-06-19 武田薬品工業株式会社 放射標識された化合物
ES2901114T3 (es) 2014-08-29 2022-03-21 Tes Pharma S R L Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa
AR109950A1 (es) 2016-10-14 2019-02-06 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
US20200000816A1 (en) 2017-02-08 2020-01-02 Ono Pharmaceutical Co., Ltd. Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
CA3119509A1 (en) 2018-11-20 2020-05-28 Tes Pharma S.R.L Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxxylase
EP3924058A1 (en) 2019-02-13 2021-12-22 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
US20230018413A1 (en) 2019-08-08 2023-01-19 Merck Sharp & Dohme Corp. Heteroaryl pyrrolidine and piperidine orexin receptor agonists
JP7443625B2 (ja) 2020-08-18 2024-03-05 メルク・シャープ・アンド・ドーム・エルエルシー ビシクロヘプタンピロリジンオレキシン受容体アゴニスト

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1921737A1 (de) * 1969-04-29 1970-11-12 Bayer Ag Heterocyclische Acylreste enthaltende Sulfonylharnstoffe und Sulfonylsemicarbazide mit antidiabetischer Wirkung
DE1933388A1 (de) * 1969-07-01 1971-01-21 Thomae Gmbh Dr K Neue Sulfonylharnstoffe und Verfahren zu ihrer Herstellung
FI49828C (fi) * 1969-07-01 1975-10-10 Thomae Gmbh Dr K Menetelmä uusien verensokeria alentavien sulfonyylikarbamidien valmist amiseksi.
CH593263A5 (US07229986-20070612-C00097.png) * 1974-02-22 1977-11-30 Hoffmann La Roche
US4170654A (en) 1976-02-13 1979-10-09 Merck & Co., Inc. Antihypertensive compositions containing N-heterocyclicalanines and α-
US4156734A (en) 1976-02-13 1979-05-29 Merck & Co., Inc. Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid
US4160835A (en) 1976-11-19 1979-07-10 Merck & Co., Inc. Antihypertensive compositions containing an arylsubstituted alanine and a phenyl hydrazinopropionic acid
JPS5465184A (en) 1977-11-02 1979-05-25 Sony Corp Production of oxidizing agent
EP0002792A1 (en) * 1978-01-03 1979-07-11 Sandoz Ag 3-Aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them
DE2934609A1 (de) 1979-08-28 1981-03-12 Cassella Ag, 6000 Frankfurt Tetrahydrochinolinderivate, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische zubereitungen.
DE3034237A1 (de) * 1979-09-18 1981-04-16 Otsuka Pharmaceutical Co. Ltd., Tokyo Carbostyrilderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende, antihistaminisch wirkende mittel
US4242346A (en) * 1979-12-19 1980-12-30 Smithkline Corporation Bis-2N-alkylene tetrahydroisoquinoline compounds
US4315935A (en) 1980-04-14 1982-02-16 Smithkline Corporation N,N'-Bis[substituted-1,2,3,4-tetrahydroisoquinolinolyl]disulfonylimides and antiallergic compositions and method of use
JPS5846515B2 (ja) * 1980-04-19 1983-10-17 帝国化学産業株式会社 インド−ル誘導体の製造方法
GB2083392A (en) 1980-09-08 1982-03-24 Graham Douglas Ian Wrench with rapid rotation facility
FR2591595B1 (fr) 1985-12-13 1988-09-09 Roussel Uclaf Nouveaux derives du 4-morpholinyl 1h-indole, leurs sels, procede de preparation, application a titre de medicaments, compositions les renfermant, et intermediaires
DE3600390A1 (de) 1986-01-09 1987-07-16 Hoechst Ag Diarylalkyl-substituierte alkylamine, verfahren zu ihrer herstellung, ihre verwendung sowie sie enthaltende arzneimittel
DE3633977A1 (de) 1986-10-06 1988-04-07 Cassella Ag Tetrahydrochinolinderivate, ein verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische zubereitungen
JPS63290821A (ja) 1987-05-25 1988-11-28 Otsuka Pharmaceut Co Ltd 抗不整脈剤
GB8717374D0 (en) * 1987-07-22 1987-08-26 Smith Kline French Lab Pharmaceutically active compounds
JPH0262875A (ja) * 1988-05-23 1990-03-02 Wakunaga Pharmaceut Co Ltd 新規イソインドリン誘導体
US5280032A (en) 1989-02-14 1994-01-18 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same
NZ232493A (en) * 1989-02-14 1992-06-25 Toyama Chemical Co Ltd Aryl- or heterocyclyl-substituted 1,2-ethanediol derivatives and pharmaceutical compositions
JPH04506967A (ja) * 1989-07-27 1992-12-03 ジー.ディー.サール アンド カンパニー 高血圧症治療用腎選択性生成物
US4963563A (en) * 1989-10-13 1990-10-16 Abbott Laboratories 6-substituted-1,2,3,4-tetrahydroisoquinolines
JPH03181478A (ja) * 1989-12-08 1991-08-07 Banyu Pharmaceut Co Ltd ピリドンカルボン酸誘導体
GR1001322B (el) 1990-04-06 1993-08-31 Panagiotis Anagnostopoulos Μηχανισμος μηχανων καμψης συρματος σε τρεις διαστασεις.
KR900016822A (ko) * 1990-04-20 1990-11-14 하라 레이노스께 슬라이드 프로젝터
AU634380B2 (en) * 1990-05-17 1993-02-18 Hoechst-Roussel Pharmaceuticals Incorporated Alpha-oxopyrrolo(2,3-b)indole acetic acids, esters, amides and related analogs, a process for their preparation and their use as medicaments
US5173497A (en) 1990-05-17 1992-12-22 Hoechst-Roussel Pharmaceuticals Incorporated Alpha-oxopyrrolo[2,3-B]indole acetic acids, esters, amides and related analogs
US5264587A (en) 1990-05-17 1993-11-23 Hoechst-Roussel Pharmaceuticals Incorporated Method of preparing α-oxopyrrolo[2,3-b]indole acetic acids and derivatives
JP3044055B2 (ja) * 1990-08-09 2000-05-22 富山化学工業株式会社 1,2―エタンジオール誘導体およびその塩
AU8333291A (en) * 1990-08-14 1992-03-17 Chugai Seiyaku Kabushiki Kaisha Novel methotrexate derivative
GB9020338D0 (en) * 1990-09-18 1990-10-31 Lilly Industries Ltd Pharmaceutical compounds
US5151435A (en) 1991-04-08 1992-09-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating an indole or dihydroindole
US5175164A (en) 1991-06-05 1992-12-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted indole or dihydroindole
JPH0717612B2 (ja) 1991-06-28 1995-03-01 ファイザー製薬株式会社 新規なテトラヒドロベンズアゼピン誘導体
DE4127404A1 (de) 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5288749A (en) * 1991-12-20 1994-02-22 Abbott Laboratories Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors
KR100248324B1 (ko) * 1992-01-27 2000-04-01 나가야마 오사무 메토트렉세이트 유도체
JP3281099B2 (ja) * 1992-02-13 2002-05-13 中外製薬株式会社 抗リウマチ剤
PH31294A (en) 1992-02-13 1998-07-06 Thomae Gmbh Dr K Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them.
TW218875B (US07229986-20070612-C00097.png) 1992-03-09 1994-01-11 Takeda Pharm Industry Co Ltd
US5462934A (en) 1992-03-09 1995-10-31 Takeda Chemical Industries Condensed heterocyclic ketone derivatives and their use
EP0597112A4 (en) * 1992-03-27 1994-06-22 Kyoto Pharma Ind Novel imidazole derivative, pharmaceutical use thereof, and intermediate therefor.
US5538973A (en) 1992-03-27 1996-07-23 Kyoto Pharmaceutical Industries, Ltd. Imidazole derivative, pharmaceutical use thereof, and intermediate therefor
JP2661841B2 (ja) * 1992-07-23 1997-10-08 ファイザー製薬株式会社 インドリン誘導体
US5541218A (en) 1992-07-23 1996-07-30 Pfizer Inc. Indolinyl N-hydroxyurea and N-hydroxamic acid derivatives as lipoxygenase inhibitors
US5374643A (en) * 1992-09-11 1994-12-20 E. R. Squibb & Sons, Inc. Aryl urea (thiourea) and cyanoguanidine derivatives
JP2913082B2 (ja) 1992-10-16 1999-06-28 大塚製薬株式会社 バソプレシン拮抗剤及びオキシトシン拮抗剤
TW270927B (US07229986-20070612-C00097.png) 1992-10-16 1996-02-21 Otsuka Pharma Co Ltd
EP0600675B1 (en) 1992-12-02 1998-07-08 Kissei Pharmaceutical Co., Ltd. Indoline compounds for the treatment of dysuria
DE4326465A1 (de) 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW242557B (US07229986-20070612-C00097.png) * 1993-02-18 1995-03-11 Ciba Geigy
JP3213426B2 (ja) * 1993-02-19 2001-10-02 エーザイ株式会社 6,7−ジヒドロ−5H−シクロペンタ〔d〕ピリミジン誘導体
US5387685A (en) 1993-07-16 1995-02-07 American Cyanamid Co MDR reversal agents
US5547966A (en) 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
GB9322976D0 (en) 1993-11-08 1994-01-05 Pfizer Ltd Therapeutic agents
US5889022A (en) 1993-12-21 1999-03-30 Smithkline Beecham, P.L.C. Indole, indoline and quinoline derivatives with 5HT1D (anti-depressive) activity
US6143791A (en) 1994-02-03 2000-11-07 Cambridge Neuroscience, Inc. Therapeutic guanidines
EP0751767A4 (en) * 1994-02-03 1997-12-10 Cambridge Neuroscience Inc GUANIDINE FOR THERAPEUTIC USE
DE69511260T2 (de) 1994-05-07 2000-03-16 Astra Ab Bicyclische amidinderivate als no-synthetase inhibitoren
JP3331048B2 (ja) * 1994-06-01 2002-10-07 キッセイ薬品工業株式会社 インドール誘導体
JP3331047B2 (ja) * 1994-06-01 2002-10-07 キッセイ薬品工業株式会社 インドリン誘導体
GB9416972D0 (en) 1994-08-23 1994-10-12 Smithkline Beecham Plc Carbon side chain/indole/indolene
EP0781773A4 (en) * 1994-09-16 1997-12-29 Banyu Pharma Co Ltd NEW CARBAPENEM DERIVATIVES
GB9424708D0 (en) * 1994-12-07 1995-02-01 Bristol Myers Squibb Co Use of inflammatory modulators in the treatment of chronic or recalcitrant skin damage
US5631280A (en) * 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1996035713A1 (en) * 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
CA2220055C (en) 1995-05-08 2001-04-24 Pfizer Inc. Dipeptides which promote release of growth hormone
GB9511355D0 (en) * 1995-06-06 1995-08-02 Fujisawa Pharmaceutical Co Urea derivatives
SK281442B6 (sk) * 1995-08-10 2001-03-12 Astra Aktiebolag Bicyklické amidínové deriváty, spôsob ich prípravy, farmaceutické kompozície s ich obsahom a ich použitie
US5767129A (en) * 1995-08-24 1998-06-16 Warner-Lambert Company Substituted quinolines and isoquinolines as calcium channel blockers, their preparation and the use thereof
GB9519077D0 (en) * 1995-09-18 1995-11-15 Fujisawa Pharmaceutical Co New heterocyclic compounds
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
CA2251625A1 (en) * 1996-04-24 1997-10-30 Yumiko Shibouta Fused imidazopyridine derivatives as antihyperlipidemic agents
US5856530A (en) 1996-05-14 1999-01-05 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
ES2242225T3 (es) * 1996-05-14 2005-11-01 Agouron Pharmaceuticals, Inc. Inhibidores de proteasas 3c antipicornavirales y procedimientos correspondientes de utilizacion y de preparacion.
JP2000512646A (ja) 1996-06-25 2000-09-26 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 5ht7受容体アンタゴニストとしてのスルホンアミド誘導体
CA2263284A1 (en) 1996-08-14 1998-02-19 Smithkline Beecham P.L.C. Tetrahydroisoquinoline derivatives and their pharmaceutical use
WO1998007719A1 (en) 1996-08-22 1998-02-26 Dong Wha Pharm. Ind. Co., Ltd. Arylsulfonylimidazolone derivatives as an antitumor agent
US6602864B1 (en) * 1996-12-13 2003-08-05 Aventis Pharma Deutschland Gmbh Sulfonic acid or sulfonylamino N-(heteroaralkyl)-azaheterocyclylamide compounds
HUP9904188A3 (en) * 1996-12-13 2003-02-28 Aventis Pharmaceuticals Inc Co Sulfonic acid or sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds
AU720466B2 (en) * 1996-12-27 2000-06-01 Hoechst Marion Roussel, Inc. N-(pyridinylamino)isoindolines and related compounds
US6004977A (en) 1996-12-27 1999-12-21 Hoechst Marion Roussel, Inc. N-(pyridinylamino) isoindolines and related compounds
AU6852898A (en) * 1997-04-17 1998-11-11 Takeda Chemical Industries Ltd. Thermogenic composition and benzazepine thermogenics
WO1998050346A2 (en) * 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
IL123986A (en) 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
DE19727117A1 (de) * 1997-06-26 1999-01-07 Boehringer Ingelheim Pharma Phenylalkylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1999033798A1 (fr) * 1997-12-25 1999-07-08 Yamanouchi Pharmaceutical Co., Ltd. Derives heterocycliques azotes
KR100576207B1 (ko) * 1998-02-27 2006-05-03 깃세이 야쿠힌 고교 가부시키가이샤 인돌유도체 및 이 유도체를 함유하는 의약품 조성물
GB9804734D0 (en) * 1998-03-05 1998-04-29 Pfizer Ltd Compounds
JP4327915B2 (ja) * 1998-03-30 2009-09-09 株式会社デ・ウエスタン・セラピテクス研究所 スルフォンアミド誘導体
IL141596A0 (en) * 1998-08-26 2002-03-10 Aventis Pharma Ltd Aza-bicycles which modulate the inhibition of cell adhesion
CN1261098C (zh) * 1998-08-28 2006-06-28 西奥斯股份有限公司 p38-α激酶的抑制剂
FR2783519B1 (fr) * 1998-09-23 2003-01-24 Sod Conseils Rech Applic Nouveaux derives d'amidines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
ES2255311T3 (es) * 1998-10-08 2006-06-16 Smithkline Beecham Plc Derivados de tetrahidrobenzazepina utiles como moduladores de los receptores d3 de dopamina (agentes anti-psicoticos).
EP1122252A4 (en) * 1998-10-16 2002-06-26 Takeda Chemical Industries Ltd CONDENSED HEREROCYCLIC NITROGEN COMPOUNDS; MANUFACTURING PROCESS AND AGENTS CONTAINING THEM
AR022230A1 (es) * 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
GB9909409D0 (en) * 1999-04-24 1999-06-23 Zeneca Ltd Chemical compounds
JP2000321732A (ja) * 1999-05-07 2000-11-24 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料および画像形成方法
JP2000321736A (ja) * 1999-05-07 2000-11-24 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料および画像形成方法
GB9929552D0 (en) * 1999-12-14 2000-02-09 Proteus Molecular Design Compounds
AU5413600A (en) * 1999-06-14 2001-01-02 Eli Lilly And Company Compounds
DE19927415A1 (de) * 1999-06-16 2000-12-21 Bayer Ag Indolinylharnstoffderivate
EP1196412B1 (en) * 1999-07-16 2004-06-09 Bristol-Myers Squibb Pharma Company Nitrogen containing heterobicycles as factor xa inhibitors
DE19934272A1 (de) * 1999-07-21 2001-01-25 Bayer Ag Neue antivirale Mittel
AU6762400A (en) * 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
AU7315800A (en) * 1999-09-20 2001-04-24 Takeda Chemical Industries Ltd. Mch antagonists
EP1218358B1 (en) * 1999-09-23 2006-09-13 AstraZeneca AB Therapeutic quinazoline compounds
ATE286883T1 (de) * 1999-11-05 2005-01-15 Smithkline Beecham Plc Isochinolin und chinazolinderivate mit kombinierter 5ht1a, 5ht1b und 5ht1d rezeptor aktivität

Also Published As

Publication number Publication date
US20030158177A1 (en) 2003-08-21
EP1283199A4 (en) 2003-12-17
US7229986B2 (en) 2007-06-12
WO2001087834A1 (fr) 2001-11-22
AU2001256733A1 (en) 2001-11-26
EP1283199A1 (en) 2003-02-12

Similar Documents

Publication Publication Date Title
US7229986B2 (en) Melanin-concentrating hormone antagonist
CA2407149C (en) Melanin-concentrating hormone antagonist
US7115750B1 (en) Melanin concentrating hormone antagonist
US7183415B2 (en) Quinoline compound
CA2383147A1 (en) Mch antagonists
JP2002003370A (ja) メラニン凝集ホルモン拮抗剤
WO2001025228A1 (fr) Derives d'amines
US20050245571A1 (en) Amine derivative
JP2004523530A (ja) メラノコルチン受容体アゴニストとしてのピペラジンおよびピペリジン誘導体
JP2002526477A (ja) Cetp阻害剤としての4−カルボキシアミノ−2−メチル−1,2,3,4−テトラヒドロキノリン類
JP2008546711A (ja) Cns障害の処置のためのヘキサヒドロ−ピロロ−イソキノリン化合物
JP2002371059A (ja) メラニン凝集ホルモン拮抗剤
JPH11514671A (ja) ムスカリン様アンタゴニストとしての1,4―ジ―置換ピペリジン
CA2506735A1 (en) Indole derivatives as somatostatin agonists or antagonists
JP2002241274A (ja) メラニン凝集ホルモン拮抗剤
JP4408618B2 (ja) キノリン化合物
WO1997011054A1 (en) Benzoic acid compounds and medicinal use thereof
ES2349624T3 (es) Antagonistas de la hormona que concentra la melanina.
JP4630555B2 (ja) アミン誘導体
JP2004300133A (ja) アミン誘導体
JP2002097138A (ja) Mch拮抗剤
JP2002348287A (ja) アミン誘導体
JP2002088079A (ja) アミン誘導体
JP2007016039A (ja) 排尿障害予防治療剤
WO2002016350A1 (fr) Dérivés amines

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead